Evidence map›Paper›PMID 42035136›Full record

ArticleBreast cancer research : BCR2026

Genomic and spatial analysis of local recurrences following risk-adapted breast radiotherapy in the IMPORT trials.

Sara V Lightowlers, Maria Roman-Escorza, Ceilidh Welsh, Judith M Bliss, Jason S Carroll, H Y Charlie Chan, Karl Harrison, Joanne S Haviland, Nuala Healy, Monica L Jefford and 10 more

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Sara V Lightowlers *Department of Oncology, University of Cambridge, Cambridge, UK. sara.lightowlers3@nhs.net.
Maria Roman-Escorza *School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, SE1 9RT, UK.
Ceilidh WelshDepartment of Oncology, University of Cambridge, Cambridge, UK.
Judith M BlissThe Institute of Cancer Research Clinical Trials and Statistics Unit, Institute of Cancer Research, London, UK.
Jason S CarrollCancer Research UK Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK.
H Y Charlie ChanDepartment of Breast Surgery, Nuffield Health Cheltenham Hospital, Cheltenham, UK.
Karl HarrisonCavendish Laboratory, University of Cambridge, Cambridge, CB3 0HE, UK.
Joanne S HavilandThe Institute of Cancer Research Clinical Trials and Statistics Unit, Institute of Cancer Research, London, UK.
Nuala HealyCambridge Breast Unit, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.
Monica L JeffordIndependent Cancer Patients Voice, London, UK.
Rajesh JenaDepartment of Oncology, University of Cambridge, Cambridge, UK.
Anna M KirbyBreast Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK.
Cliona C KirwanDivision of Cancer Sciences, University of Manchester, Manchester, UK.
Elena ProvenzanoNIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Mark A SydenhamThe Institute of Cancer Research Clinical Trials and Statistics Unit, Institute of Cancer Research, London, UK.
Isabel SyndikusDepartment of Radiotherapy, Clatterbridge Cancer Centre, Bebington, UK.
James TannerCambridge Breast Unit, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK.
Ramona WoitekDepartment of Radiology and Cancer Research UK Cambridge Center, Cambridge, CB2 0QQ, UK.
Charlotte E Coles *Department of Oncology, University of Cambridge, Cambridge, UK.
Elinor J Sawyer *School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, Guy's Cancer Centre, King's College London, London, SE1 9RT, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIpsilateral breast tumour recurrences (IBTR) that occur after breast-conserving surgery (BCS) and breast radiotherapy may be ‘true recurrences’ or independent ‘new primaries’. Contralateral breast cancers (CBC) are usually assumed to be new primary tumours. Understanding the patterns of occurrence of these entities, and/or being able to reliably distinguish between the two, could have important implications for tailoring patient management at primary presentation and at IBTR/CBC diagnosis.

methodsThe clonal relationship between index, and ipsilateral and contralateral subsequent breast tumours was assessed in 112 paired samples from two breast radiotherapy trials, IMPORT LOW and IMPORT HIGH, using copy number profiling and targeted sequencing of DNA. The spatial relationships between the index tumour beds, radiotherapy dose distributions and subsequent tumours were analysed via computational co-registration of cross-sectional imaging.

resultsIn the IMPORT HIGH cohort, where patients were at higher risk of IBTR, 61% of IBTRs were clonally related to the index tumour compared with only 32% from the IMPORT LOW cohort. There was no difference in the spatial distributions relative to index tumour beds of related compared to unrelated subsequent tumours. Related IBTRs occurred in a higher proportion of those diagnosed less than 5 years after index treatment, compared with those diagnosed after 5 years (66% vs. 24%). Four of 18 CBCs in the IMPORT HIGH cohort, but none from IMPORT LOW, were genomically similar to the index cancers.

conclusionsThese findings show that IBTRs near the index tumour bed are not always true recurrences and also strongly suggest that some CBCs are metastases.

Indexed as

Breast NeoplasmsGenomicsNeoplasm Recurrence, LocalAdultAgedDNA Copy Number VariationsFemaleHumansMastectomy, SegmentalMiddle AgedSpatial AnalysisBreast cancerBreast radiotherapyLocal recurrenceRisk-adapted radiotherapyTumour evolution

Identifiers

PMID42035136
PMCPMC13267394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.